About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
Multi-media
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
EN
简体
EN
繁體
Home
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
搜索
Be the most trusted biotech company
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Popular Science
Highlights
Download
Media Reports
Media Enquiry
2025-06-25
Henlius Doses First Patient in Japanese Bridging Study of Serplulimab for Extensive-Stage Small Cell Lung Cancer
2025-06-24
Serplulimab Approved in the UK and India for the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer
2025-06-20
Henlius Shines at 2025 BIO International Convention, Showcasing Its Innovative Achievements
2025-06-13
Expanding Southeast Asian Presence: Serplulimab Approved in Singapore and Malaysia
2025-06-10
First Subject Dosed for a Phase 2 MRCT of Henlius’ PD-L1-Targeting ADC HLX43 for the Treatment of NSCLC
2025-06-09
Henlius Showcases Global Innovation Momentum at Jefferies Global Healthcare Conference 2025
2025-06-06
Henlius Hosts Global Oncologists Reception During ASCO 2025, Highlighting Innovation and Collaboration
2025-06-04
Updated results and biomarker analysis from the Pivotal Clinical Trial ASTRUM-005 of Serplulimab Published on Cancer Communications
2025-06-03
Results from the Phase 1 Clinical Trial of Henlius PD-L1 ADC HLX43 Released at 2025 ASCO Annual Meeting
1
2
3
...
45
